We are incredibly proud of our collaboration with the Pierre Fabre Group in developing a user-friendly and informative app that empowers colorectal cancer patients to take control of their health.
From concept to launch, our team has been dedicated to creating an app that embodies the BioLizard vision of improving the quality and longevity of human life around the world by better leveraging data.
We are thrilled to see the positive impact that our app will have on patients’ lives, and we hope that it continues to be a valuable resource for anyone affected by colorectal cancer.
If you haven’t checked out our app yet, find it here – available for Android or iOS.
For over a century, the life sciences industry has relied on animal models as the standard for predicting drug safety and effect. But today, the industry faces a harsh reality: over 90% of new drugs that appear safe and effective in animal tests ultimately fail in human clinical trials (see for example Ineichen et al. 2024 [1] and Marshall et al. 2023[2])
Oncology drug development often begins in patients, allowing early safety and efficacy insights. Yet many cancer drugs still fail in the clinic. We validate the target but ignore its context within the tumor microenvironment. This article explores why spatial biology may improve clinical success.
BioLizard has been named “Bioinformatics Innovation of the Year” in the 2025 BioTech Breakthrough Awards. The honor spotlights Bio|Verse® Navigator, a visual analytics workspace that unifies complex R&D data so scientists can decide faster, with confidence.
